ALXO | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 25%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.94%

1 Month

-10.60%

3 Months

46.26%

6 Months

102.83%

1 Year

124.10%

2 Year

-82.62%

Key data

Stock price

$2.15

P/E Ratio

3.65

DAY RANGE

$2.04 - $2.15

EPS

-$2.10

52 WEEK RANGE

$0.40 - $2.66

52 WEEK CHANGE

$158.60

MARKET CAP

97.999 M

YIELD

N/A

SHARES OUTSTANDING

54.218 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

0.56

PUBLIC FLOAT

AVERAGE 10 VOLUME

$571,945

AVERAGE 30 VOLUME

$831,726

Company detail

CEO: Jaume Pons
Region: US
Website: alxoncology.com
Employees: 40
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ALX Oncology Holdings Inc. focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial. ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

ALXO - Alx Oncology Holdings Inc